Spelling suggestions: "subject:"digoxin."" "subject:"digoxina.""
1 |
Investigations on digoxin : a study of the effect of cholestyramine on digoxin elimination in humans, development of an HPLC assay for urinary lipid-soluble cardenolide metabolites and dihydrodigoxin, and a study of the epimeric forms of... /Bockbrader, Howard N. January 1979 (has links)
No description available.
|
2 |
Intestinal secretion of organic solutesCavet, Megan Elizabeth January 1996 (has links)
No description available.
|
3 |
The development of a self-instructional programmed course on digitalis for collegiate nursing studentsTagliente, Mary Savina January 1964 (has links)
Thesis (M.S.)--Boston University / PLEASE NOTE: Boston University Libraries did not receive an Authorization To Manage form for this thesis or dissertation. It is therefore not openly accessible, though it may be available by request. If you are the author or principal advisor of this work and would like to request open access for it, please contact us at open-help@bu.edu. Thank you. / 2031-01-01
|
4 |
Studies on the evidence base in support of digoxin therapeutic drug monitoring.Shakib, Sepehr January 2007 (has links)
Title page, table of contents and abstract only. The complete thesis in print form is available from the University of Adelaide Library. / There is a dearth of high level evidence for the benefit of digoxin therapeutic drug monitoring on clinical endpoints. A pilot randomised controlled trial of digoxin TDM was conducted in hospital inpatients. The benefit of the knowledge of the serum digoxin concentration (SDC) in determining the likelihood of digoxin toxicity was assessed by presenting blinded clinicians clinical and SDC data using a computerised interface. The main benefit of the knowledge of the SDC was to reduce the percentage of patients classified as "possibly toxic", and to increase the agreement between clinicians. The study found that an increase in the prevalence of cardiac and non-cardiac manifestations of digoxin toxicity became clear at approximately 1.0 ng/ml which is at the lower end of the currently quoted therapeutic range. / http://proxy.library.adelaide.edu.au/login?url= http://library.adelaide.edu.au/cgi-bin/Pwebrecon.cgi?BBID=1274191 / Thesis (Ph.D.) -- University of Adelaide, School of Medical Sciences, 2007
|
5 |
Applications of a new logic to old drugs: angiogenesis inhibition in neuroblastoma /Svensson, Åsa, January 2003 (has links)
Diss. (sammanfattning) Uppsala : Univ., 2003. / Härtill 4 uppsatser.
|
6 |
Pharmacogenomics of antihypertensive treatment & clinical pharmacological studies of digoxin treatment /Hallberg, Pär, January 2005 (has links)
Diss. (sammanfattning) Uppsala : Uppsala universitet, 2005. / Härtill 5 uppsatser.
|
7 |
Characterization of monoclonal antibodies against digoxin /Alexandrovich, Susan K. January 1987 (has links)
Thesis (M.S.)--Rochester Institute of Technology, 1987. / Typescript. Includes bibliographical references (leaves 42-43).
|
8 |
Untersuchungen über den Einfluss von Äthanol auf die Liberation und Resorption von Acetylsalicylsäure und Digoxin aus TablettenpräparatenSchwabe, Lothar, January 1978 (has links)
Thesis (doctoral)--Freie Universität Berlin, 1978.
|
9 |
HPLC analysis of digoxin and digitoxin : development of methods for dosage form assay and separation of potential impurities and metabolitesDesta, Belachew January 1982 (has links)
The objective of this investigation was to develop quantitative isocratic HPLC methods for the analysis of digoxin and digitoxin. An HPLC system that employs a reverse-phase column, UV detection at 220 nm and solvent systems consisting of various proportions of water, methanol, isopropanol and dichlormethane was developed for the separation of digoxin, digitoxin and their potential degradation products and metabolites.
HPLC separations of the above compounds by isocratic, solvent switchover and gradient elution modes were carried out in chromatographic times of 27, 16 and 13 minutes, respectively.
For purposes of monitoring the separation of dihydro metabolites of digoxin, a 100% fluid recovery system was developed for use in the HPLC analysis of digoxin and its metabolites after fluorogenic post-column derivatization using the air-segmentation process.
As an evidence of selectivity, the isocratic HPLC systems were utilized for the separation of a mixture of ten closely related steroids and the isolation of digitoxin from Digitalis purpurea leaf.
The isocratic HPLC systems were found to be applicable for the quantitative analysis of digoxin and digitoxin in their respective dosage forms. The HPLC assay of digoxin and digitoxin dosage forms was carried out in less than forty-five minutes. These methods were found to be precise, accurate, sensitive enough for single tablet assay, and capable of simultaneously monitoring the potential degradation products or metabolites of digoxin and digitoxin.
A comparison of the assay of digoxin and digitoxin dosage forms
by HPLC and USP methods indicated that: (a) the precision and accuracy of both methods were comparable and within acceptable limits; (2) analysis by HPLC can be completed in less than forty-five minutes whereas the USP methods require over four hours; and (3) the HPLC methods have the advantages of higher sensitivity, selectivity and simplicity over the USP methods.
The HPLC methods were used for the stability study of digoxin and digitoxin in their respective dosage forms. Lanoxin and digitoxin tablets were found to be stable under all the conditions of storage used in this study. Natigoxin tablets, Lanoxin injection and elixir were found to be subject to varying degrees and patterns of degradation. On the basis of the stability results it was observed that the assortment of pathways that may be involved at different conditions and times of storage'would make it difficult to estimate digoxin shelf-life from data obtained by accelerated aging.
From the results of this investigation, it was concluded that the isocratic HPLC methods were suitable for the assay of digoxin and digitoxin dosage forms as well as for purposes of stability testing and simultaneous monitoring of degradation products or metabolites.
This abstract represents the true contents of the thesis submitted. / Pharmaceutical Sciences, Faculty of / Graduate
|
10 |
Digoxin pharmacokinetics and biovailability in man /Kramer, William G. January 1976 (has links)
No description available.
|
Page generated in 0.0311 seconds